A report on the safety of acitretin use in patients with renal failure on haemodialysis
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llae093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Paul Jaehoon Shim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA. Hauptthemen laut MEDLINE: Acitretin, Renal Dialysis, Kidney Failure, Chronic, Psoriasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Gefördert von: CSRD VA, Chinese Academy of Medical Sciences, Innovation Fund for Medical Science.
Abstract (Originalsprache)
Acitretin, commonly used for severe psoriasis and keratinocyte carcinoma chemoprevention in high-risk patients, is contraindicated in patients with end-stage renal disease (ESRD) on haemodialysis (HD). However, these patients often lack medication choices and in certain clinical scenarios the benefits of acitretin may outweigh the potential risks. We identified 24 patients with ESRD on HD undergoing acitretin treatment from the Duke and Vanderbilt University Medical Centers. While adverse effects were common, they were not a frequent cause of treatment discontinuation among patients. We also found no association between acitretin treatment and hospital admissions or mortality. Lastly, we found statistically significant increases in alkaline phosphatase (ALP; P = 0.03) and total bilirubin (P < 0.001) when patients were receiving acitretin and HD compared with baseline. However, there was no dose dependency or temporal association with acitretin or HD initiation. Based on these preliminary findings, we find that acitretin may safely be used in patients receiving HD, with close monitoring of ALP and bilirubin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.
- Department of Dermatology, Duke University School of Medicine, Durham, NC, USA.
- Department of Dermatology, Vanderbilt School of Medicine, Nashville, TN, USA.
- CAMS Oxford Institute, University of Oxford, Oxford, UK.
- Oxford Kidney and Transplant Unit, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- Tennessee Valley Healthcare System VA Medical Center, Nashville, TN, USA.
ORCID-Profile: Paul Jaehoon Shim, Melodi Javid Whitley
Förderung
- CSRD VA
- Chinese Academy of Medical Sciences
- Innovation Fund for Medical Science
- US Department of Veterans Affairs Clinical Sciences R&D Service
Zitieren
APA
Shim, P. J., Quintos, J. L., Faraz, K., Smith, I. T., Petty, A. J., Bottomley, M., Wheless, L. E., & Whitley, M. J. (2024). A report on the safety of acitretin use in patients with renal failure on haemodialysis. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llae093
Vancouver
Shim PJ, Quintos JL, Faraz K, Smith IT, Petty AJ, Bottomley M, et al. A report on the safety of acitretin use in patients with renal failure on haemodialysis. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llae093
BibTeX
@article{Shim2024,
author = {Shim, Paul Jaehoon and Quintos, Jessica Leigh and Faraz, Khushnood and Smith, Isabelle Taylor and Petty, Amy Jiayue and Bottomley, Matthew and Wheless, Lee Emerson and Whitley, Melodi Javid},
title = {A report on the safety of acitretin use in patients with renal failure on haemodialysis},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llae093}
}
EUVIMED